Archive | January, 2010

Life Science Sector Performance: ETF’s and Funds Feb 12 mos.YTD

In a volatile sell-off day involving tech stocks, the biotech world was relatively calm. Despite good news on corporate earnings and a GDP with an annual 5.7% annual growth, investors chose to take profits even on solid player like Microsoft down over 3% today. Market Strength is routinely being sold. Biotech stocks stayed out of […]

Continue Reading 0

Biomedical stocks beat the bleak

Large Cap biomedical stocks held firm on another volatile but down day in the market driven by a host of macro and fundamental factors: earnings, Davos, Greece,China, politics, Bernanke confirmation, strong dollar, jobs, etc. In this convoluted market the technology leader Apple ( PE 26.6,EPS $7.49) with their iPad launch does not threaten Amazon’s (PE […]

Continue Reading 0

Gilead Sciences revenues and profits up sharply on antiviral drugs

Gilead (GILD) shares were up 6% to $47.75 after the close as the Company announced record sales and earnings. Full Year total Revenues were $7.01B up 31% over 2008. Full Year Non-GAAP EPS were $3.06 up 40% over 2008. Fourth Quarter Non-GAAP EPS were $0.93 up 49% over 2008. Average analysts revenue estimates for 2010 […]

Continue Reading 0

Amgen Earnings just OK; January effect for BIO topped out

AMGN-Top line revenue slowing One of the largest biotech companies reported earnings within estimates with full year 2009 EPS of $4.91 up 8% on Revenue of $14.6B down 2%.2010 Total Revenue is expected to be in the $15.1B to $15.5B range with adjusted EPS at $5.05 to $5.25.U.S. Product Sales were $11.13B a decrease of […]

Continue Reading 0

Waxman Power Play to squeeze Biotech for “biogenerics”

It is hard to believe but the Obama administration wants to open up a new political front at the last minute to squeeze the biotechnology industry after everyone thought the 12 year protection from generic biologicals was a “done deal”. http://www.genengnews.com/articles/chitem.aspx?aid=2717 Last-ditch lobbying battle over biotech drugs By ALAN FRAM The Associated Press Thursday, January […]

Continue Reading 0

JPMorgan Healthcare Conference 2010: Themes and News

Here are some of the broader themes and market trends gleaned from Company presentations: 1.) There is a shift from small molecule drug development to biologicals and vaccines. e.g. Pfizer (PFE) 2.) “Bolt-on” acquisitions of smaller companies are being done to bolster product portfolios and emerging market positions. e.g. GSK 3.) There is increasing synergy […]

Continue Reading 0

JPMorgan Healthcare Conference-2010 Day One-Monday January 11

Over 5000 people piled into the Westin St. Francis Hotel in San Francisco for the 28th Annual Conference. Investors, Company presenters and entrepreneurs were emboldened by good biotech sector returns in 2009 of 18-28% with many stocks reaching new highs. Seasonality has been a factor with the so-called “January effect” where small cap stocks tend […]

Continue Reading 1

JPMorgan Healthcare Conference Jan.11-14 San Francisco

We will be attending the 28th Annual JPMorgan Healthcare Conference in San Francisco and reporting on various companies and news on the Genetic Engineering News WEB site (www.genengnews.com). Although we will be attending presentations of companies in all sectors we will try to focus on the following: Diagnostics e.g, GenProbe, Idexx, Inverness Genomics e.g. Celera, […]

Continue Reading 0

Volcano(VOLC) erupts 9% on Upgrade

Robert W. Baird and Co. analyst Lawrence Neibor upgraded four medtech stocks and helped get the “January effect” in full swing. Cyberonics (CYBX), Edwards Lifescience (EW), Thoratec (THOR) and Volcano (VOLC) were all upgraded to Outperform from Neutral. Volcano was up 9% to 19 in late afternoon trading on 640k shares and is up about […]

Continue Reading 0